Evidence map›Paper›PMID 42104549›Full record

ArticleChemMedChem2026

Inhibitors Targeting SARS-CoV-2 Papain-Like Protease: Screening, Design, Synthesis, and Biological Evaluation.

Elena-Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Correa Verissimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael Victorio Carvalho Guido, Anthony J O'Donoghue and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elena-Oriana IugaInstitute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Eberhard Karls University, Tübingen, Germany.
Nilu GoneInstitute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Eberhard Karls University, Tübingen, Germany.
Mariana Ortiz de GodoySão Carlos Institute of Physics, University of São Paulo (USP), São Carlos, Brazil.
Gabriel Correa VerissimoFaculdade de Farmácia, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.
Giovanna de Jesus AgostinettoFaculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Liam UrichSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Nadine KrügerPlatform Infection Models, German Primate Center, Leibniz Institute for Primate Research Göttingen, Göttingen, Germany.
Thales KronenbergerSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Rafael Victorio Carvalho GuidoSão Carlos Institute of Physics, University of São Paulo (USP), São Carlos, Brazil.
Anthony J O'DonoghueSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Stefan A LauferInstitute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Eberhard Karls University, Tübingen, Germany.
Thanigaimalai PillaiyarInstitute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Eberhard Karls University, Tübingen, Germany.ORCID https://orcid.org/0000-0001-5575-8896

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the availability of vaccines and antiviral drugs, SARS-CoV-2 still presents a global health threat, emphasizing the need for new therapeutic targets beyond the main protease and RNA-dependent RNA polymerase. The papain-like protease (PL

Indexed as

Antiviral AgentsCoronavirus Papain-Like ProteasesDrug DesignProtease InhibitorsSARS-CoV-2AnimalsCOVID-19 Drug TreatmentHumansMolecular Docking SimulationStructure-Activity RelationshipAntiviral AgentsCoronavirus Papain-Like Proteasespapain-like protease, SARS-CoV-2Protease InhibitorsantiviralCOVID‐19non‐covalent inhibitorspapain‐like proteaseSARS‐CoV‐2

Identifiers

PMID42104549
PMCPMC13156432

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.